Exhibit 23.1
CONSENT OF REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
Durata Therapeutics, Inc:
We consent to the use of our report dated March 21, 2012, except for the first four paragraphs of Note 11, which are as of June 21, 2012, and the fifth paragraph of Note 11, which is as of July 9, 2012, included herein, and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Short Hills, New Jersey
July 9, 2012